HopeStage
Back to all studies
CompletedNCT00237913

Aripiprazole or usual care for schizophrenia

About this titleRead the official source — NCT00237913
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Vienna and 32 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2004
Recruitment status
Completed
Enrollment listed in the registry
700
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France, United Kingdom, Austria, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00237913
Official title
Show the full official title

A Multicenter, Randomized, Naturalistic, Open-Label Study Between Aripiprazole and Standard of Care in the Management of Community-Treated Schizophrenic Patients (Schizophrenia Trial of Aripiprazole - STAR)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Vienna, Austria · Přerov, Czechia · Copenhagen, Denmark

31 more locations
  • Hørsholm, Denmark
  • Helsinki, Finland
  • Brumath, France
  • Dole, France
  • Hénin-Beaumont, France
  • Jonzac, France
  • Nantes Orvault, France
  • Paris, France
  • Reims, France
  • Rennes, France
  • Toulouse, France
  • Uzès, France
  • Duisburg, Germany
  • Hattingen, Germany
  • München, Germany
  • Nuremberg, Germany
  • Oldenburg, Germany
  • Murcia, Spain
  • Bromma, Sweden
  • Gothenburgh, Sweden
  • Halmstad, Sweden
  • Malmö, Sweden
  • Säter, Sweden
  • Belfast, United Kingdom
  • London, United Kingdom
  • Royal Tunbridge Wells, United Kingdom
  • Glasgow, United Kingdom
  • Davyhulme, United Kingdom
  • South Wales, United Kingdom
  • Birmingham, United Kingdom
  • Czechia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole and Olanzapine or Quetiapine or Risperidone.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies